Jazz Pharmaceuticals (JAZZ) jumped 4.89% over the past two days after announcing better-than-expected earnings. Quarterly revenues increased 67.7% year over year to $208.3 million. Second-quarter 2013 adjusted earnings of $1 per share were well above the year-ago earnings of 81 cents per share.
With your September 2013 $70.000 calls (JAZZ130921C00070000) now up 101.64%, sell all of your remaining options to lock in these triple-digit percentage gains.
With Jazz Pharmaceuticals (JAZZ) up 40.99% since my initial recommendation on May 13, raise your stop in the stock to $78.30 to lock in at least a 35% gain in the stock.
Fall 2013: Rise of the Small Caps? (YahooFinance)
With both the S&P 500 and Russell 2,000 within two percent of their all time highs, investors may want to pay more attention to the small caps in the second half of 2013, if for no other reason than simple mathematics. You see, the top five positions in the S&P 500 make up 10% of the small-cap index’s total
Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:
Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.
Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:
Jon Johnson's philosophy in investing and trading is to take what the market gives you regardless if that is to the upside or downside. For the past 21 years, Jon has helped thousands of clients gain success in the financial markets through his newsletters and education services: